Clinical Trial Detail

NCT ID NCT01683994
Title Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

prostate cancer

Therapies

Cabozantinib + Docetaxel

Age Groups: adult

No variant requirements are available.